

IN THE SPECIFICATION

Please delete the first paragraph of the amended "Summary of the Invention,"
at page 5 and replace with the following:

21 - - The present invention provides a vaccine formulation suitable for mucosal administration, the vaccine includes a mixture of a virus-like particle (VLP) comprising a surface antigen from a virus, and a non-living vaccine antigen, the surface antigen having an adjuvant effect on said vaccine antigen. Each vaccine dose includes up to about 1 milligram each of the surface antigen and vaccine antigen. The vaccine formulation may include one or more of the following: a preservative, a stabilizer and a second vaccine antigen. - -

At page 6, please delete the paragraph extending from line 13 to line 16 and replace with the following:

22 - - It is possible to obtain a wider spectrum of immune response generated by HBcAg regarded as an important antigen *per se* in anti-HBV VHB protection. Furthermore, the IgG seric levels anti-HBsAg reached by mucosal inoculation is as intense as the one obtained with the systemic inoculation in alum. - -
